Tarleton Communications

Antibody-drug conjugates (ADCs) are a rapidly emerging class of targeted therapy that epitomise the potential of recent advances in applied chemical biology 🔬 But where is ADC discovery today and what do the commercialisation prospects of this ‘smart’ chemotherapeutic look like as we steam towards the next decade? Our Biotechnology Sector Lead, Nick Massouh, gives his take on ADCs and considers the global outlook. https://lnkd.in/eienT52U #biotech #ADCs #antibodydrugconjugates #drugdiscovery

February is coming to an end, and so we're looking back on what we've been up to this month 📣 - We secured a prime time interview on Sky News to discuss Motor Neurone Disease and assisted dying 📺 - Managing Director Thomas Averre spoke with Pioneer Group about the importance of PR when raising investment and scaling 📈 - Account Executive Tom Horn was featured in the launch edition of health journal., discussing Health Tech trends 🩺 - Biotechnology Sector Specialist Nick Massouh wrote about Antibody Drug Conjugates (ADCs) and the need to clearly communicate the value proposition to investors 💰 - We continued to deliver coverage for all our clients across national and specialist industry publications 📰 We have a big announcement being unveiled next week - more news soon! #skynews #biotech #healthtech #tech #science #mnd

Yesterday, Thomas Averre and Nick Massouh were in Bloomsbury talking to life science companies about how to manage their reputation and strengthen relationships as they raise investment and scale.    Thomas was invited by Pioneer Group to speak to over 15 companies about the work we do at Tarleton and how we've helped clients to establish reputations and raise their profile ahead of key milestones.    We work with many spinouts, and some of the UK's leading universities, to help commercialise IP and influence critical stakeholders.    Find out more about what we do: https://lnkd.in/eGGpHDTQ   #pioneer #biotech #venturecapital #labspace

We’re delighted that Tarleton secured a primetime interview on Sky News yesterday. MND sufferer Andrew Davies and wife Milica were interviewed on ‘The UK Tonight’, Sky’s flagship UK news show. The couple discussed living with MND, the assisted dying bill, and the lack of treatments and cures available to MND patients. You can watch the full interview here: https://lnkd.in/eCpZRJX8 #MND #AssistedDying #SkyNews

Yesterday's announcement on defence spending was a definitive statement of intent from the government: security is now one of the government's top priorities, and we'll soon see fresh opportunities emerging in this area. It's well known that procurement and technology adoption are key areas for improvement within the MoD. Combined with the spending increase, this offers a major opportunity for British defence tech companies. But only for those which make themselves heard. At Tarleton, we help you to amplify your voice within government through public affairs support, networking opportunities, political insights briefings, and PR and media relations. Sound relevant? Get in touch. With the defence environment changing so rapidly, there is no time to lose. #Defence #DefenceSpending #PublicAffairs

In an increasingly unstable world, there's a lot of discussion about increasing defence spending and developing new defence tech. But there's already plenty of activity and opportunity within the sector. Defence, resilience and security tech is receiving 10% of all venture capital funding in Europe, a record high, and NATO and the UK have this week launched a Defence Innovation Accelerator for the North Atlantic. Companies including UK based Metahelios ltd will see their solutions used for military and civilian purposes by members of the alliance. Initiatives like this are only going to become more common, as focus on defence increases. Companies should think about how their offerings can be used in a defence context to capitalise on this in the coming months and years. #Defence #NATO #Accelerator https://lnkd.in/ejU9AccU.

Discussion is rife about the impact of President Trump's return on the biotech industry. This piece from Yogan A Patel from client MHA explains the opportunities and challenges another Trump Presidency brings British life sciences. #Trump #LifeScience #Biotech https://lnkd.in/e2NXZDW5

The health technology landscape is evolving faster than ever, with growing amounts of data and new types of devices materialising. So what are the key trends and themes emerging? In this article for health journal, Tarleton Account Executive Tom Horn explains. #HealthTech #HealthTrends https://lnkd.in/dkHGKQmU

Yesterday, we attended Health Innovation Yorkshire & Humber’s Women in Healthcare event 👩🔬 It was great to hear female entrepreneurs share the barriers they faced to launching healthcare startups, and how they overcame them. Throughout the discussion, the issues of disparities in funding, hostile pitching environments, childcare and lack of confidence were raised as barriers to success. Finding solutions to these problems should be a top priority for the healthcare community. As yesterday’s event shows, failing to meet the needs of female innovators means there is a great deal of potential which is being left untapped. #femtech #womeninhealthcare #healthinnovation

Missed what we've been up to? Here's some of our January highlights 🚀   - We refined our brand and welcomed our new biotechnology lead Nick Massouh! 💊 - We secured coverage for The Mark Sommerville Foundation and Nevrargenics Ltd. on BBC Radio Scotland and BBC Radio Tees' flagship shows 📻 - Account Executive Tom Horn wrote about changes at Sky News and the evolution of the media landscape 📣 - Managing Director Thomas Averre launched a Substack newsletter on tech, science and politics 📰 - We joined an expert discussion on the future of the NHS at Durham University, exploring the strengths and weaknesses of the Darzi Report and where it should go next Stay tuned for more big announcements this month!